artelo
biosciences
reports
fourth
quarter
fiscal
financial
results
provides
business
update
closed
million
underwritten
public
offering
received
ethics
approval
commence
cares
study
uk
expanded
exclusive
worldwide
license
stony
brook
university
fatty
acid
binding
protein
inhibitor
platform
la
jolla
globe
newswire
artelo
biosciences
nasdaq
artl
clinical
stage
biopharmaceutical
company
focused
development
therapeutics
modulate
endogenous
signaling
pathways
including
endocannabinoid
system
today
reported
financial
operating
results
fourth
quarter
fiscal
year
ended
august
provided
business
update
pivotal
year
artelo
notable
clinical
operational
progress
alongside
successful
financing
advance
programs
toward
meaningful
milestones
stated
gregory
gorgas
artelo
president
ceo
significantly
poised
initiate
enrollment
cancer
appetite
recovery
phase
clinical
study
cares
lead
program
end
addition
artelo
expanded
agreement
stony
brook
university
rights
inhibitors
treatment
cancer
pain
inflammation
expanding
potential
established
program
result
key
priorities
clinical
execution
cares
study
strategic
partnership
discussions
programs
continued
gorgas
additional
corporate
highlights
include
received
ethics
approval
united
kingdom
commence
cares
study
treatment
anorexia
successfully
manufactured
clinical
study
material
selected
contract
research
organization
cares
study
treatment
anorexia
expanded
license
agreement
stony
brook
university
inhibitor
platform
development
lead
cancer
pain
inflammation
compounds
platform
earlier
year
earned
stony
brook
million
nci
development
grant
filed
method
use
patent
patent
trademark
office
uspto
covering
use
inhibitors
treatment
psychological
disorders
anxiety
stress
disorder
ptsd
received
first
composition
matter
patent
claims
related
company
cocrystal
solid
form
cbd
uspto
enabling
protection
fiscal
year
end
financial
results
operating
expenses
year
ended
august
compared
period
increase
operating
expenses
year
ended
august
primarily
related
increase
general
administrative
fees
research
development
expenses
net
loss
approximately
per
basic
diluted
share
year
ended
august
compared
net
loss
per
basic
diluted
share
year
ended
august
august
company
approximately
cash
compared
august
artelo
biosciences
artelo
biosciences
san
biopharmaceutical
company
dedicated
development
commercialization
proprietary
therapeutics
targeting
endogenous
signaling
pathways
including
endocannabinoid
system
artelo
rapidly
advancing
portfolio
broadly
applicable
product
candidates
designed
address
significant
unmet
needs
multiple
diseases
conditions
including
anorexia
cancer
pain
inflammation
led
proven
biopharmaceutical
executives
collaborating
highly
respected
researchers
technology
experts
company
applies
leading
edge
scientific
regulatory
commercial
discipline
develop
therapies
information
available
twitter
artelobio
forward
looking
statements
press
release
contains
certain
statements
within
meaning
section
securities
act
section
securities
exchange
act
private
securities
litigation
reform
act
amended
including
relating
company
product
development
clinical
regulatory
timelines
market
opportunity
competitive
position
possible
assumed
future
results
operations
business
strategies
potential
growth
opportunities
statement
predictive
nature
statements
based
current
expectations
estimates
forecasts
projections
industry
markets
operate
management
current
beliefs
assumptions
statements
may
identified
use
expressions
including
limited
expect
anticipate
intend
plan
believe
estimate
potential
predict
project
would
similar
expressions
negatives
terms
statements
relate
future
events
financial
performance
involve
known
unknown
risks
uncertainties
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
factors
include
set
forth
company
filings
securities
exchange
commission
including
ability
raise
additional
capital
future
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
press
release
company
undertakes
obligation
publicly
update
statement
whether
result
new
information
future
events
otherwise
except
extent
required
applicable
securities
laws
investor
relations
contact
crescendo
communications
llc
tel
email
artl
